DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability by Verstappen, M. (M.) et al.
ORIGINAL ARTICLE
DMARD-free remission as novel
treatment target in rheumatoid arthritis:
A systematic literature review of
achievability and sustainability
M Verstappen ,1 E van Mulligen ,2 P H P de Jong,2 A H M van der Helm-
Van Mil 1,2
ABSTRACT
Objectives Although current treatment guidelines for
rheumatoid arthritis (RA) suggest tapering disease-modifying
anti-rheumatic drugs (DMARDs), it is unclear whether
DMARD-free remission (DFR) is an achievable and
sustainable outcome. Therefore, we systematically reviewed
the literature to determine the prevalence and sustainability
of DFR and evaluated potential predictors for DFR.
Methods A systematic literature search was performed in
March 2019 in multiple databases. All clinical trials and
observational studies reporting on discontinuation of
DMARDs in RA patients in remission were included. Our
quality assessment included a general assessment and
assessment of the description of DFR. Prevalence of DFR
and its sustainability and flares during tapering and after
DMARD stop were summarised. Also, potential predictors
for achieving DFR were reviewed.
Results From 631 articles, 51 were included, comprising
14 clinical trials and 5 observational studies. DFR definition
differed, especially for the duration of DMARD-free state.
Considering only high- and moderate-quality studies, DFR
was achieved in 5.0%–24.3% and sustained DFR
(duration>12 months) in 11.6%–19.4% (both relative to the
number of patients eligible for tapering). Flares occurred
frequently during DMARD tapering (41.8%–75.0%) and in
the first year after achieving DFR (10.4%–11.8%), while late
flares, >1 year after DMARD-stop, were infrequent (0.3%–
3.5%). Many patient characteristics lacked association with
DFR. Absence of autoantibodies and shared epitope alleles
increased the chance of achieving DFR.
Conclusions DFR is achievable in RA and is sustainable in
~10%–20% of patients. DFR can become an important
outcome measure for clinical trials and requires consistency
in the definition. Considering the high rate of flares in the
first year after DMARD stop, a DMARD-free follow-up of >12
months is advisable to evaluate sustainability.
INTRODUCTION
In rheumatoid arthritis (RA), early treatment,
with disease-modifying antirheumatic drugs
(DMARDs), aiming at sustained remission, is
nowadays the key element of each manage-
ment approach.1 2 As a result, RA has become
a controllable disease in which sustained clin-
ical remission is achievable for an increasing
number of patients, and tapering and discon-
tinuation of DMARDs have become of emer-
ging interest.3 Current international
guidelines recommend tapering of DMARDs
in RA patients with sustained remission.1 2
Nevertheless, these guidelines are less clear
whether DMARDs can be stopped, and the
systematic literature review supportive of the
most recent EULAR guidelines was not
focused on DMARD cessation.4
Despite the recommendations in the guide-
lines, tapering of DMARDs has not been
adopted structurally in many clinical prac-
tices, presumably because the risk of
a disease flare5 and because the ability to
achieve and sustain DMARD-free remission
(DFR) is often considered unlikely.6 On the
other hand, there is increasing interest in
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Key messages
What is already known about this subject?
► Although current treatment guidelines for rheumatoid
arthritis suggest tapering DMARDs when patients are
in sustained remission, it is unclear whether DMARD-
free remission is an achievable and sustainable
outcome.
What does this study add?
► DMARD-free remission is achievable in rheumatoid
arthritis and is sustainable in ~10%–20% of
patients.
How might this impact on clinical practice or
future developments?
► DMARD-free remission can become an important
outcome measure for clinical trials, though this
requires consistency in the definition.
► We propose to incorporate a DMARD-free follow-up
period for at least 1 year, to ensure that DMARD-free
remission is sustainable.
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achieving DFR, because this is currently the best proxy for
cure.7 8 Clinical trials occasionally report on DFR, but
usually not as the primary outcome. Absence of knowl-
edge of DFR prevalence, its sustainability and the char-
acteristics of patients achieving DFR currently hamper
the use of DFR as primary outcome.9
We aimed to expand the comprehension of the ability
to achieve and sustain DFR in RA. Therefore, we con-
ducted a systematic literature search. In addition to the
DFR prevalence and sustainability, potential predictors
for achieving DFR were explored.
METHODS
Search strategy and selection criteria
This systematic literature review was conducted in accor-
dance with the Preferred Reporting Items for Systematic
Review and Meta-Analysis (PRISMA) guidelines and the
Cochrane review handbook.10 11 The protocol was regis-
tered in the International Prospective Register of Sys-
tematic Reviews (CRD42019132558).12
The search strategy was developed and performed in
collaboration with an experienced librarian (JS). Key
terms used for the search were ‘Rheumatoid arthritis’,
‘Antirheumatic drugs’, ‘Discontinuation’ and ‘Remission’.
These search items were translated intomultiplematching
synonyms in order to broaden our results. All search ele-
ments were combined with the Boolean operators AND/
OR. PubMed, Embase, Web of Science, COCHRANE
Library, Emcare and Academic Search Premier were sys-
tematically searched (supplementary table S1).
All observational cohorts and clinical trials reporting on
discontinuation of DMARDs in RA patients, in remission,
were included. Study selection was independently carried
out by two reviewers (MV and EvM). Cases of disagree-
ment were discussed until consensus was reached. First,
all obtained titles were screened, and subsequently
abstracts were reviewed after which full-text articles were
screened for the predefined inclusion and exclusion cri-
teria (supplementary table S2). If multiple articles were
based on the same study, the article which described the
prevalence and sustainability of DFR most clearly was
selected. Subsequently, the article describing the longest
follow-up was used for data extraction.
Data extraction
A standardised data collection form was used to extract the
following information: study design, patient characteristics,
interventions, glucocorticoids (GCs) usage, organisation of
follow-up, outcome measures and loss to follow-up (supple
mentary table S3). Furthermore, data regarding eligibility
criteria for tapering, taperingmethods, numbers of patients
tapering, description and timing of achieving DFR, sustain-
ment of DFR over time and the occurrence of flares were
extensively explored. Also, information regarding predic-
tors of DFR was collected. Data extraction was done inde-
pendently by two reviewers (MV and EvM), and
disagreements were discussed until consensus was reached.
If the methods were incomplete or unclear, the meth-
ods of the original study could be used if a reference was
available. Clinical trials and observational studies were
handled separately, because of fundamental differences
in the study design, which could influence achievement
and sustainment of DFR, that is, protocolised versus non-
protocolised tapering, frequency ofmonitoring and dura-
tion of follow-up.
Quality assessment
Our study quality assessment consisted of two parts, namely
a general assessment and an assessment of the description
of DFR. For the general quality assessment, we used 13
predefined quality criteria, which were based onCochrane
guidelines (supplementary table S4).11 The general study
quality was considered ‘good’ if >75% (≥10 items) of these
criteria were scored positive. For the DFR quality assess-
ment, we used the following criteria: (1)‘DFR definition’,
referring to whether a definition (eg, remission criterion)
of DFR was included, and (2)‘DFR duration’, referring to
whether information on the time between DMARD stop
and being appointed as DFR (i.e. the duration of DMARD-
free status) was reported. Specific emphasis was put on the
duration ofDMARD-free state since this attains insight into
the sustainability of DFR. When both DFR quality criteria
were scored positive, DFR quality was regarded as ‘good’.
Studies were regarded as ‘high quality’ if the general
quality, as well as the DFR quality, was good. When the
general study quality was good but only oneDFR-criterion
was fulfilled, studies were regarded as ‘moderate quality’.
Studies lacking both DFR criteria, or without a good gen-
eral quality assessment, were scored as ‘low quality’.
Data analysis
Extracted data were used to calculate DFR prevalence,
defined as the proportion of patients achieving DFR,
compared with those eligible for tapering medication.
For each prevalence, the CI was calculated. Patients
were considered eligible for tapering when they had
achieved remission and subsequently were allowed to
start tapering their medication. GCs were also considered
as DMARDs. We specifically chose not to use the total
study population as the denominator, because in some
studies specific groups of patients were not allowed to
taper their medication due to study protocol.
Sustained DFR (SDFR) was defined as the percentage of
patients with a DFR duration of >12 months since DMARD
stop, relative to the number of patients eligible for tapering.
Reported flares were categorised and summarised accord-
ing to the time period in which they occurred: (i) during
tapering, (ii) in the first year after achieving DFR (‘early
flares’) and (iii) aftermore than1 year ofDFR (‘late flares’).
Results on DFR were summarised in a narrative overview,
also in relation to study quality. Due to expected hetero-
geneity in study design and study populations, pooled effect
estimates were not calculated.
Additionally, the data were reviewed on potential pre-
dictors for achieving DFR. We used the samemethods for
RMD Open
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data extraction and assessment as described for DFR pre-
valence. Predictors of DFR were summarised. Results on
variables evaluated in more than one high-quality or
moderate-quality article were graphically presented,
based on statistical significance obtained with regression
analysis. If univariate and multivariate analyses were both
conducted, results of the multivariate analysis were used.
For each predictor, the number of studies and the total
number of patients within these studies were presented
and the direction of the effect was indicated.
RESULTS
Study selection
Our search resulted in 631 articles, of which 51 articles
were considered eligible for inclusion (figure 1). These
51 articles comprised data from 19 studies, 14 clinical
trials and 5 observational cohorts.
Quality assessment
Both the quality of the study in general and the descrip-
tion of DFR were evaluated, resulting in a final quality
rating. Eleven out of 14 clinical trials and two out of five
observational cohorts showed a good general quality
(table 1). Notably, the tapering methods were better
described for clinical trials than for observational cohorts.
Of the 13 studies with a good general quality, seven ful-
filled both quality criteria for DFR and were regarded as
high quality. These seven high-quality studies comprised
five clinical trials and two observational cohorts. Of the
remaining six studies, two studies were of moderate qual-
ity since only one DFR criterion was fulfilled. The four
other studies did not fulfil any DFR quality criteria and
were regarded low quality (table 1).
Because of fundamental differences in study design, DFR
prevalence and flare rates from clinical trials and observa-
tional cohorts were presented separately. Also, only high-
quality or moderate-quality studies were presented in the
result section. Nonetheless, all prevalence, including those
of low-quality studies, can be found in table 2.
Clinical trials
Study characteristics
Study populations varied in RA classification (1987 vs
2010 criteria), disease stage/duration (early vs estab-
lished) and disease activity (supplementary table S5).
Overall, trials were performed in two ‘settings’: early,
DMARD-naïve RA and established RA. Studies including
early RA had a treat-to-target approach, and when remis-
sion was achieved, DMARDs were tapered. This was all
conducted in a relative short period of time (n=7).13–19
The established RA studies (disease duration 3.1–11.3
years, n=6) either included patients with active disease
who first changed DMARD treatment and subsequently
became eligible for tapering (n=2)20 21 or selected
patients who were in longstanding remission and were
directly considered eligible for tapering (n=4).22–25 All
established RA studies were of low quality, except 1 which
was of moderate quality.18 One study, including patients
in sustained remission, did not report disease duration.19
DMARD tapering
Tapering of DMARDs was initiated when patients fulfilled
the study-specific eligibility criteria for tapering, in which
some were stricter than others (supplementary table S5).
Methods of tapering varied from immediate DMARD stop
to one-by-one gradual tapering of DMARDs over the
course of a year. In general, tapering of biologic DMARDs
took place before tapering of conventional synthetic
DMARDs. Flare rates during tapering ranged from
41.8% to 75.0% (table 2, figure 2).
Definitions of DMARD-free remission
Overall, the remission criterion used to define DFR was
mainly DAS44 or DAS28 remission. The DFR rates were
either given as a point prevalence, thus at the moment of
DMARD stop, or combined with aminimal DFR period of
several months (table 2, figure 2). Nevertheless, most
studies did not putmuch emphasis on aminimal duration
of the drug-free state as a requirement to achieve DFR.
Importantly, three studies that clearly defined DFR (two
high-quality, one moderate-quality) allowed i.a. or oral
GCs during DFR, without reporting the actual use.13 17 18
Prevalence of DMARD-free remission
In the five high-quality clinical trials, the reported preva-
lence of DFR (DFR <12 months) ranged from 5.0% to
24.3% (relative to the number of patients eligible for
tapering). The two moderate-quality studies reported
a DFR prevalence of 5.9% and 21.9% (table 2, figure 2),
respectively. When studies that allowed GCs while being
in DFR were excluded, DFR occurred in 5.0%–23.0%.
SDFR (DFR >12months) was only reported in two clinical
trials and showed a prevalence of 11.6% and 19.4% (rela-
tive to patients eligible for tapering).
Evaluation of DFR prevalence, in high-quality andmod-
erate-quality studies, in relation to the trial ‘settings’ was
hampered by the fact that only one study was performed
in established RA where DMARDs were tapered after
prolonged remission,18 revealing a DFR prevalence of
5.9% compared with the prevalence of 5.0%–24.3% in
studies that tapered DMARDs in early RA.13–17 32
Early flares (≤12 months after DMARD-stop) were
reported in one high-quality study and occurred in
10.4% of patients eligible for tapering. Late flares (>12
months after DMARD-stop) were reported by another
study and occurred in 3.5% of patients (table 2).
Observational cohorts
Study characteristics
Patients included in the observational cohorts were diag-
nosed between 1986 and 2011 (n=5). Patients in the obser-
vational cohorts were, compared with clinical trials,
included in an earlier time period, but had a longer follow-
up. Diagnosis was based on the 1987 criteria27 29 31 or
Rheumatoid arthritis
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expert opinion.28 30 Treatment was less protocolised com-
pared with the clinical trials, and a treat-to-target approach
was only used in three studies,27–29 of which two had a high
quality (table 2).
DMARD tapering
Eligibility for tapering was only clearly reported in one
study.28
Definitions of DMARD-free remission
Remission within DFR was defined as the absence of
clinical synovitis (table 2), except for one study that
used a DAS28 cut-off (DAS28<2.6).28 All five observa-
tional cohorts reported on SDFR (DFR >12 months),
whereas one also reported on DFR after 6 months. In
two studies, of which one was a high-quality study, i.a.
and oral GC were allowed while being in DFR; the actual
use was not reported.
Prevalence of DMARD-free remission
DFR prevalence (<12 months) was 23.6% of patients eli-
gible for tapering and was reported in one high-quality
study.28 The prevalence of SDFR ranged from 11.8% to
17.8% (relative to patients eligible for tapering)(table 2,
Figure 2).27 28 If we exclude the studies that allowed GCs
during DFR, one high-quality study remained with an
SDFR prevalence of 17.8%.27 We did not compare DFR
prevalence between studies that did and did not apply
a treat-to-target approach, because all studies without
a treat-to-target approach were of low quality.
Early flares (≤12 months after DMARD stop) were
reported in one high-quality study and occurred in
Records identified through
database searching
(duplicates removed)
(n=631)
Included titles
(n=466)
Included abstracts
(n=138)
Articles excluded based on title
(n=165)
Articles excluded based on abstract
(n=328)
Articles included in analysis
(n=51)
Full‐text articles excluded (n=87)
Full text not available (n=8)
No discontinuation of all DMARDs (n=43)
DMARD discontinuation not clearly described (n=20)
Other type of literature: reviews, correspondence, case‐reports (n=10)
Focus on discontinuation DMARDs due to adverse events,
not due to remission (n=6)
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11.8% of patients eligible for tapering. Late flares were
reported by the other high-quality study and were seen in
0.3% of patients eligible for tapering (table 2).
Predictors of DFR
All factors that were analysed for their potential associa-
tion with achieving DFR were evaluated (supplementary
table S6). Due to heterogeneity in evaluated effect esti-
mates, effect sizes could not be compared and meta-
analyses not performed. For predictors that were studied
in more than one high-quality or moderate-quality study,
the association with achieving DFR is summarised in fig-
ure 3 (see also supplementary table S7). The figure
includes information on the number of studies with/with-
out an association with DFR, the total number of patients
in these studies and the directionality of the effect (if
present). The absence of autoantibodies and HLA-
shared epitope alleles were predictive for achieving
DFR. Many patient characteristics (eg, age, body mass
index, swollen joint count (SJC), estimated sedimenta-
tion rate (ESR), erosions at baseline) were not associated
with the chance of achieving DFR. For some, character-
istic findings were inconsistent. Results on symptom dura-
tion, for example, showed ambiguous results
(supplementary table S6/7).
DISCUSSION
This systematic literature review was conducted in accor-
dance with PRISMA guidelines and provides insight into
the occurrence and sustainability of DFR in RA. The
prevalence of DFR (DFR≤12 months) was 5.0%–
24.3%,14–17 32 while SDFR (DFR>12 months) was achiev-
able in 11.6%–19.4% of patients eligible for tapering.
Remission criteria used to define DFR varied widely,
and the temporal aspect (sustainability) varied as well or
was not reported. Moreover, in some studies, concomi-
tant use of GC was allowed while patients were in DFR.
This might falsely inflate DFR prevalence, but to what
extent this occurred is unclear as actual use was not
reported. Exclusion of aforementioned studies did not
affect our results. To increase homogeneity, quality cri-
teria were used, and final conclusions were only based on
high-uality and moderate-quality studies, which resulted
in a narrative overview of DFR prevalence (figure 2).
We observed different DFR prevalence depending on
the duration of the DFR period. To allow a fair compar-
ison of DFR prevalence, we categorised the duration of
DFR in groups. SDFR was defined as a DMARD-free per-
iod >12 months. Higher prevalence was observed when
DFR had a less stringent criterion for sustainability (fig-
ure 2). In line with this, flares occurredmost often during
tapering and in the first months after DMARD stop. This
time effect underlines the relevance of defining sustain-
ability of DFR in future studies.
DFR and SDFR might be fundamentally different.
Short-term DFR might indicate that disease activity was
suppressed, but not necessarily resolved, and could reviveTa
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after the disappearance of suppressive treatment. More-
over, early flares (≤12 months after DFR) occur more
often than late flares (>12 months after DFR), which
might indicate that autoimmunity was not completely
silenced. In our opinion, patients in SDFR (DFR>12
months) better resemble silencing of autoimmunity and
may have achieved a proxy for cure. Therefore, SDFR can
become an important outcome for clinical trials. Because
late flares (often occurring years after DMARD-stop)
might be pathophysiologically different from early flares,
it is an interesting subject for future studies to explore the
triggers or pathophysiologic mechanisms involved in late
reactivation of the autoimmune process.
Notably, despite differences in study design, the DFR
prevalence observed in observational cohorts and clinical
trials was comparable. This supports the robustness of the
observed frequencies. We were unable to investigate how
long remission should be sustained before tapering can
be initiated, because too few high-quality studies were
performed in patients with established RA and longstand-
ing remission. Additionally, due to an insufficient
amount of studies, nothing can be said about the change
of achieving DFR after treatment with certain conven-
tional or biologic DMARDs.
We could not evaluate whether the method of tapering
influenced the frequency of SDFR. It has been suggested
that gradual tapering results in less flares compared with
abrupt cessation.2 Also, the stringency of the remission
criterion for initiation of tapering might be of influence,
whereby less stringent criteria might increase the risk of
flares. Evaluation of themethods of DMARD tapering was
beyond the scope of this review, and a relevant subject for
further studies as insight into the most effective tapering
method may positively influence the chance to achieve
SDFR. Another issue for further studies is the assessment
of the likelihood to achieve remission for patients that
flare after having been in DFR. From studies on patients
that flared during tapering, it is known that the majority
of patients achieve remission by restarting the same
DMARD.33 Whether this is similar for patients that flare
after DMARD stop is not yet systematically studied.
Studying the prevalence of DFR and predictors for DFR
does not answer the question whether the absence of
clinical signs and symptoms without treatment exhibited
the natural course of RA in these patients,34 or was
induced by DMARD treatment. This could not be
answered within our SLR, nor could we compare studies
for treatment intensity (eg, reflected by treat-to-target)
due to the lack of high-quality studies without a treat-to-
target approach. One high-quality study compared
a treat-to-target approach that aimed for a DAS<1.6 with
an approach that aimed for a DAS<2.4 and reported that
patients achieved DFR more often when aimed for
a DAS<1.6 (18% vs 8%, respectively), suggesting that
intensive treatment is helpful in inducing DFR.35 How-
ever, the clinical trials rarely used DFR as a primary out-
come, and, therefore, the question to what extent the
frequency of DFR can be achieved by treatment remains
a subject for future studies.
Although we tried to find predictors for DFR, it remains
uncertain which patients are able to stop their DMARDs
successfully. Meta-analyses could not be performed due
to the heterogeneity of studies and effect estimates.
Therefore, we summarised and graphically presented
data on predictors using predefined criteria, but this
methodology is far less optimal than meta-analysis. Sev-
eral patient characteristics (eg, age, SJC, ESR and erosive-
ness) were not associated with a higher chance of
achieving DFR. Results on symptom duration were con-
flicting, as the relation between DFR and symptom
Figure 2 Summary of flare rate and DFR prevalence, all as percentage of the number of patients that were eligible for DMARD
tapering, depicted on a timeline. DFRprevalencewasgroupedby the duration ofDFR.Data are presented asDFRpercentage (CI). Data
were based on high-quality or moderate-quality studies. Prevalence andCIs were calculated using the number of DFR patients divided
by the number of patients eligible for tapering. Results from observational studies are indicated in italic. *indicates that studies that
allowed the use of i.a. or systemic corticosteroids in patients that were considered to be in DFR(absolute number of patients that used
corticosteroids after DMARDstopwas not reported) or use inDMARD-free statuswasnot clearly reported. X indicatesmoderate-quality
studies. DMARD, disease-modifying antirheumatic drugs; DFR, DMARD-free remission; SDFR, sustained DMARD-free remission.
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duration was non-significant, but showed a strong ten-
dency towards significance in part of the studies. Further-
more, it is known that the association with DFR is not
linear but refined to a short period of time30 (ie, the
window of opportunity), and associations may remain
undetected if symptom duration is analysed as
a continuous variable. Absence of autoantibodies was
the best predictor for DFR. Although effect sizes were
not involved in our analyses, the absence of autoantibo-
dies alone is not sufficient to accurately guide taper deci-
sions in daily practice. Therefore, effective pursuit of
SDFR in clinical practice requires more insight into sub-
sets of patients that are likely to achieve SDFR.
Acknowledging the importance of the autoantibody
status as predictor, the SDFR prevalence will be different
for autoantibody-positive and autoantibody-negative
patients. We could not stratify the results on SDFR pre-
valence for autoantibody status as the prevalence
reported in the included cohorts and trials was not always
stratified for autoantibodies. However, the studies that
included information on autoantibody status in their
patient characteristics reported that 52%–100% of
patients were autoantibody positive (supplementary
table S5).
Since conducting a thorough systematic literature
review is time demanding, a time gap exists between
-2000 -1000 0 1000 2000
Shared epitope (y/n)
Erosive at baseline (y/n)
(higher) SHS score at baseline
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(higher) ESR
(higher) HAQ at baseline
(higher) SJC at baseline
(higher) DAS at baseline
Symptom duraon
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Size of combined study populations
Not associated with achieving DFR
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Positively associated with achieving DFR
3
2
1
0
1
1
2
0
1
0
0
0
0
2
2
1 2
1
2
1
1
1
2
2
12
2
2
1
2
Not associated Associated
Figure 3 Overview of studied predictors of achieving DMARD-free remission. Data are presented from variables that were
reported in >1 study, based on statistical significance obtained in regression analysis. If both univariable and multivariable
regression was applied, the result of the multivariable regression was used. Presented are the absence (left panel) and presence
of an association with achieving DFR over time (right panel), the number of studies is indicated per predictor, the total number of
patients in these studies is plotted on the x-axis. The directionality of the effect is indicated in colours, green indicates an
increased risk of achieving DFR, red indicates a decreased risk of achieving DFR. For symptom duration, no differentiation was
made for analyses using this as continuous or categorical variable. BMI, body mass index; CRP, C reactive protein; DAS,
Disease Activity Score; ESR, estimated sedimentation rate; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor;
SJC, swollen joint count.
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the actual literature search (March 2019) and publica-
tion of the results. As a result, relevant articles in this
time interval are not included. A non-systematic screen-
ing of articles published in this period revealed the
BioRRA study,36 published in December 2019. This
study focuses on predictors of flare after DMARD cessa-
tion and reported a 52% flare rate (DAS28-CRP≥2.4)
after abrupt DMARD cessation. Predictors of flares
were, among other things, absence of Boolean remission
at baseline, RF positivity and IL-27. Biomarkers predic-
tive of DFR, as identified in other recent studies, were
calprotectin levels and several serum protein levels
among which SAA.37 38 Calprotectin and SAA are both
acute phase reactants. However, none of these markers
were yet validated in independent studies.
From the patients’ perspective, achieving SDFR is ben-
eficial; it was recently reported to be associated with
normalisation of functional disability and resolution of
symptoms, for example, fatigue.27 Unfortunately, clini-
cal trials infrequently evaluated SDFR. If future trials
would be designed with DFR/SDFR as primary outcome,
consensus of the definition of remission and the dura-
tion of DMARD-free state is required to promote com-
parability of findings between studies. This may require
OMERACT Initiatives.
In conclusion, DFR is achievable in RA and is sustainable
in ~10%–20% of patients. DFR can become an important
outcome measure for clinical trials and requires consis-
tency in the definition. Considering the relative short fol-
low-up after DMARD stop in current clinical trials and the
high rate of flares in the first year after DMARD stop, we
propose to incorporate a DMARD-free follow-up of at least
1 year, to ensure that DFR is sustainable.
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